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Abstract 
 
Recent evidence suggest that soluble oligomeric Aβ assemblies are critically involved in the 
pathogenesis of Alzheimer disease (AD). We have generated a conformation-dependent 
monoclonal antibody (9D5) that selectively recognizes low-molecular weight AβpE3 
oligomers, and demonstrated its diagnostic and therapeutic potential. Here, we further 
characterize the specificity of this antibody by evaluating a spectrum of neurodegeneration-
related protein deposits for cross-reactivity, and by comparing the staining pattern of 9D5 
with a generic Aβ antibody that targets a linear epitope (mAb NT244), and with another 
conformation-dependent Aβ antibody that selectively labels amyloid fibrils of various 
molecular weights (pAb OC). The 9D5 antibody does not cross-react with other aggregated 
protein deposits in brains of progressive supranuclear palsy, corticobasal degeneration, 
argyrophilic grain disease, Pick`s disease, Parkinson disease, dementia with Lewy bodies, 
multiple system atrophy, frontotemporal lobar degeneration or amyotrophic lateral sclerosis 
with TDP-43 inclusions, Creutzfeldt-Jakob disease, and vessel changes in Binswanger 
encephalopathy, demonstrating the specificity of 9D5 for Aβ deposits. While NT244 and OC 
showed a comparable plaque load, 9D5 detected only approximately 15% of the total Aβ 
plaque load in the entorhinal cortex, the CA1 region and the temporal neocortex. Our study 
further supports a possible therapeutic advantage of 9D5 by the highly specific recognition of 
an epitope found only in oligomeric assemblies of AβpE3 of AD patients. Moreover, selective 
binding to only a pathogenetically relevant fraction of Aβ deposits serves as rationale for 
passive immunisation with 9D5-derivatives by limiting potential side effects of vaccination 
due to dissolvement of existing amyloid deposits.  
 
 
 
 
 
 
 
 
Key words: Alzheimer disease; amyloid; immunohistochemistry; conformation-dependent 
antibodies; oligomers; proteinopathy; pyroglutamate; neurodegenerative disease; N-truncated 
Abeta;  
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Introduction 
Alzheimer disease (AD) represents a common progressive neurodegenerative disorder 
that is characterized neuropathologically by extracellular deposits composed of the amyloid-
β (Aβ) protein and intracellular accumulation of phosphorylated tau protein [1]. Intra- or 
extracellular deposition of proteins is a feature of neurodegenerative diseases and serves as a 
molecular pathologic basis for classification as proteinopathies [2]. While immunoreactivity 
for Aβ or prion protein (PrP) is located predominantly extracellularly, proteins that deposit 
intracellularly include tau, α-synuclein, or TAR DNA Binding Protein 43 (TDP-43). 
Deposition of these proteins show considerable overlap [2]. Tauopathies include progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease 
(AGD), all predominated by the 4R isoform of the tau protein, and Pick`s disease (PiD), a 3R 
tauopathy. Alpha-synucleinopathies comprise Parkinson`s disease (PD), dementia with Lewy 
bodies (DLB), and multiple system atrophy (MSA). TDP-43 proteinopathies include a group 
of frontotemporal lobar degenerations (FTLD-TDP), as well as sporadic amyotrophic lateral 
sclerosis (ALS) cases, while the most frequent form of prion disease is sporadic Creutzfeldt-
Jakob disease (CJD). 
Aβ peptides deposit in form of amyloid plaques or as cerebral amyloid angiopathy 
(CAA). Morphologically, Aβ deposits can be categorized as diffuse plaques, subpial band-
like, lake-like, or fleecy deposits, and classical cored as well as so called burned-out plaques 
[3], reflecting a maturation process from early prefibrillar deposits to plaques with amyloid 
tinctorial properties. In analogy to the continuous progression and anatomical distribution 
pattern of neurofibrillary tangles according to Braak and Braak stages [4], Aβ pathology also 
follows a chronological progression course and appears in distinct susceptible brain regions, 
including temporal neocortex, entorhinal cortex and CA1 region [5, 6] 
Several reports have demonstrated that Aβ peptides may adopt different molecular 
assembly states, including soluble monomers and oligomers as well as fibrillar forms [7, 8]. 
The latter forms represent the end product of a progressive misfolding process lastly resulting 
in the fomation of insoluble amyloid plaque [9, 10]. While extracellular plaques display only 
a minor degree of toxicity and cannot be correlated to the extent of neuronal and cognitive 
alterations [11], novel concepts propose the toxicity of Aβ-derived diffusible ligands 
(ADDLs) or soluble toxic oligomers [12, 13]. Indeed, studies in transgenic mice harboring a 
novel APP mutation (E693Δ), causing preferentially Aβ oligomers without any development 
of extracellular fibrillar Aβ deposits have shown that intracellular oligomers correlate with 
extensive neuronal cell death, impaired synaptic plasticity and lead to severe cognitive 
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decline [14]. In the past, several different oligomeric assemblies and species of Aβ have been 
described in vitro and in AD brain specimen [15, 16]. However, it is currently not clear 
which toxic assemblies are most relevant in AD pathogenesis [17]. 
Aβ displays a variety of N- and C-terminal truncations even in the same plaques [18]. 
N-terminal truncations modulate aggregation kinetics and resistance towards proteolytic 
degradation. In addition to C-terminal variations such as Aβ1-40 and Aβ1-42, several N-
terminal truncated Aβ versions have been identified in AD brains. Saido et al. elucidated the 
predominant presence of AβpE3 (N-terminal truncated Aβ starting with pyroglutamate) in 
plaques of AD brains [19]. The formation of N-terminal pyroglutamate (pE) is catalyzed by 
glutamate cyclase (QC), an enzyme that was found significantly up-regulated in AD brains. 
Interestingly, selective overexpression of AβpE3-42 within neurons induced neurodegeneration 
and caused a severe neurological phenotype [20]. Furthermore, pharmacologic intervention 
via QC-inhibitors resulted in reduced Aβx-40/42 levels, decreased plaque formation and 
improved memory performance [21]. Taken together, these results implicate the potential of 
AβpE3-42 derivatives as valuable therapeutic and diagnostic target strategies in AD. In this 
regard, we recently generated a novel monoclonal antibody (9D5) that selectively detects 
oligomeric assemblies of AβpE3 [22]. In contrast to other Aβ antibodies, the conformation-
specific antibody 9D5 is made against a neoepitope and selectively identifies structural 
determinants of soluble nonfibrillar oligomers.  
Insoluble deposits and diffusible oligomers from various proteinopathies may share 
common structural epitopes [7]. Indeed, conformation-dependent antibodies may recognize a 
common neo-epitope resulting in a cross-reactive response to various aggregation-prone 
proteins [23, 24]. Thus, in the present study, we extend our previous findings and further 
characterize the antibody 9D5 using an immunohistochemical approach. We 1) analyse a 
cohort of neurodegenerative diseases to determine potential cross-reactivity of 9D5 with 
other proteins; and 2) characterize and quantify 9D5 immunoreactivity of Aβ accumulation 
in sporadic AD and age-matched non-demented brains in comparison with a generic Aβ 
antibody (mAb NT244) and another conformational specific polyclonal antibody (pAb OC) 
[24]. The current study demonstrates the lack of cross-reactivity of 9D5 to other 
neurodegeneration-related protein aggregates and recognizes only a small proportion of total 
Aβ plaque deposition.  
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Materials and methods 
 
Case selection 
We performed our study on cases characterized neuropathologically according to 
recently published protocols [25], including seven cases with AD-related pathology in 
addition to two AD cases with concomitant limbic TDP-43 deposits, and three cases each of 
DLB, PD, MSA, PSP, PiD, CBD, AGD, FTLD-TDP, ALS, sporadic CJD (including MM-1, 
MV-2 and VV-2 subtypes [26];), and a single patient with Binswanger disease. Demographic 
data and examined anatomical regions are summarized in Table 1. Cases were obtained from 
the archives of the Institute of Neurology, Medical University of Vienna (Vienna, Austria) in 
the frame of a study (“Molecular neuropathologic investigation of neurodegenerative 
diseases”) approved by the Ethical Committee of the Medical University of Vienna. In 
addition, we included ten aged-matched control (Co) patients obtained from the Netherlands 
Brain Bank (NBB, Amsterdam, Netherlands) and cortical frozen sections from an AD case 
by the University of Leipzig. 
 
Immunohistochemistry 
Formalin-fixed paraffin-embedded sections were used to detect amyloid-β (Αβ) 
deposits by immunhistochemistry (IHC) as described previously [27]. In brief, 4 µm paraffin 
sections mounted on glass slides were deparaffinized in xylene and rehydrated in ethanol. 
After blocking of the endogenous peroxidase activity by 0.3% hydrogen peroxide in 
methanol, either (A) no pretreatment; or the following epitope retrieval methods were 
applied: (B) 60-min in a steamer in 0.01 M citrate buffer pH 6.0; (C) 60-min in a steamer in 
0.01 M citrate buffer pH 6.0 followed by 3 min formic acid (98%) treatment, and (D) 1 hour 
incubation in 80% formic acid. Adjacent sections of AD brain samples including temporal 
and entorhinal cortex, and hippocampus were immunostained using the following anti-Aβ 
antibodies: antibody 9D5 that detects a conformational neoepitope (mouse monoclonal, 
1:100, University Medicine Goettingen and Synaptic Systems [22]), the conformation-
dependent antibody OC that recognizes fibrils and soluble fibrillar Aβ oligomers of various 
molecular weights (rabbit polyclonal, 1:1000, generous gift of C. Glabe [24]), and the 
commercially available antibody NT244 detecting generic Aβ (generated by immunizing 
with Aβ1–16; mouse monoclonal, 1:1000, cat. no. #218211, Synaptic Systems). All primary 
antibodies were incubated overnight in a humidified chamber at 4°C. Sections were 
subsequently incubated with a horseradish peroxidase-conjugated polymer, which carries 
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antibodies to rabbit and mouse immunoglobulins (Envision™+/HRP, Dako, Glostrup, 
Denmark), and signals were visualized with the highly sensitive 3,3´-diaminobenzidine plus 
(DAB+) (Dako). Counterstaining was carried out with hematoxylin. As negative control, the 
primary antibody was replaced with blocking solution. To further evaluate the specificity of 
antibody 9D5, we applied the following mouse monoclonal antibodies: anti-tau AT8 (pS202, 
1:200, Pierce Biotechnology, Rockford, IL, USA), anti-phospho-TDP-43 (pS409/410, 
1:2,000, Cosmo Bio, Tokyo, Japan), anti-α-synuclein (1:10,000, clone 4D6, Signet, Dedham, 
MA, USA), and anti-PrP (1:1,000, 12F10, Cayman Chemical, Ann Arbor, MI, USA).  
Frozen tissue sections from the area 7 of an AD case were prepared and stained with 
9D5 (1:100) after blocking of the endogenous peroxidase activity by 0.3% hydrogen 
peroxide in methanol followed by 10 min formic acid (98%) treatment and developed with 
streptavidin/biotinyl-peroxidase method using nickel-enhanced diaminobenzidine as 
chromogene.  
 
Double immunoluorescence labeling and laser confocal microscopy 
Double immunolabeling was performed using the monoclonal antibody 9D5 (1:100) 
and the rabbit polyclonal anti-Aβ40 antibody (1:200; Signet, Dedham, MA, USA detects the 
C-terminus of Aβ40 and does not cross-react with Aβ42 or APP) and pretreatment protocol C 
(see above). The fluorescence-labeled secondary antibodies were Alexa Fluor (AF) 555 
donkey anti-mouse IgG (1:200; Molecular Probes, Inc., Eugene, OR, USA), and AF 488 goat 
anti-rabbit (1:200; Molecular Probes, Inc.). We evaluated the double fluorescence labeling 
with a Zeiss LSM 510 confocal laser microscope.  
 
Morphometric assessment of Aβ deposits 
Adjacent sections of 400x magnification were stained with the three Aβ antibodies 
(9D5, OC, and NT244) and subsequently photographed with an Olympus DP-50 camera. 
Extent of Aβ staining was evaluated in entorhinal cortex (EC), gyrus temporalis superior 
(GTS) and in the hippocampal region CA1. After maximal separation from background 
tissue, a fixed intensity threshold was applied to select brown-colored chromogen (DAB)-
stained pixels in the same selected areas of each antibody. The images were then converted to 
black and white and quantitation of black pixels was performed using the Image J software 
(version 1.41o, National Institutes of Health). Quantitation of staining parameters were 
displayed as integrated optical density (arbitrary unit). In addition, we semiquantitatively 
evaluated different deposits (diffuse, cored plaques, primitive plaques, vascular deposits) in 
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subregions CA1, CA4, dentate gyrus, subiculum, entorhinal, and temporal cortices from the 
AD cases.  
 
Statistical analysis 
Statistical differences were calculated using one-way analysis of variance (ANOVA) 
followed by unpaired t-tests as indicated. All data are given as means ± SEM. Significance 
levels of unpaired t-tests are given as follows: ***p < 0.001; **p < 0.01; *p < 0.05. All 
calculations were performed using GraphPad Prism version 5.00 (GraphPad Software, San 
Diego, CA, USA).  
 
Results 
 
Comparison of various epitope retrieval methods 
The Envision™+ detection system used is a standarized and sensitive detection method [28]. 
In order to optimize the staining procedures, we performed comparative analysis of different 
antigen retrieval methods (see details in material and methods) and compared 
immunoreactivity of extracellular Aβ-plaques and CAA. 9D5 provided a strong and specific 
staining of Aβ deposits in vessels even without antigen retrieval (Supplemental Fig. 1). In 
terms of detecting extracellular Aβ deposits, the combined heat and FA antigen retrieval 
protocol (protocol ”C”) unequivocally demonstrated the highest staining intensity of certain 
Aβ plaques. For further specificity and comparative studies, we used this combined 
pretreatment (Fig. 1). In addition, we immunostained fresh-frozen tissue from a sporadic AD 
case: 9D5 antibody stains Aβ deposits only with formic acid pretreatment (Supplemental 
Fig. 2) 
 
9D5 antibody presents no cross-reactivity with other aggregated protein deposits 
The following pathological structures showed no immunoreactivity using 9D5 antibody 
(Fig. 2): 
1) Phospho-Tau immunoreactive structures, including neurofibrillary tangles in AD and 
PSP, tufted astrocytes (PSP), astrocytic plaques (CBD) and oligodendroglial coiled 
bodies in PSP and CBD, dystrophic neurites in AD, Pick bodies in PiD, and grains in 
AGD. 
2) α-Synuclein immunopositive Lewy bodies (brainstem and cortical) and Lewy neurites 
in PD and DLB, and glial cytoplasmic inclusions in MSA. 
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3) Phospho-TDP-43 immunoreactive neuronal cytoplasmic and neuritic deposits in 
FTLD-TDP, ALS, and AD with limbic TDP-43 deposits. 
4) PrP immunopositive amyloid plaques, synaptic, plaque-like, and perineuronal 
deposits. 
In addition, we did not observe any immunoreactivity associated with small vessel disease in 
Binswanger disease.  
 
Antibody 9D5 immunostains only a fraction of Aβ deposits in AD brains 
When evaluating different forms of Aβ deposits, we could document the maturation 
process of amyloid plaques with the antibody 9D5, starting from occasional intraneuronal 
cytoplasmic dots, seen only in the presubiculum and entorhinal cortex of the examined AD 
cases, through perineuronal deposition to granulo-fibrillar diffuse, primitive, and cored 
plaques (Fig 3A, C, E). However, the extent of visualized Aβ fibrils was much less in  
comparison with NT244 immunolabeling (Fig. 3B, D, F). This was further supported by 
double labeling with Aβ40  antibody (Fig. 3G). Thus, while antibody 9D5 immunolabeled all 
subtypes of Aβ deposits (Figs. 3A, C, E and 4A), morphometric evaluation of 
immunodeposits in three different anatomical regions demonstrated significantly less extent 
and intensity of immunoreactivity using the 9D5 antibody as compared to NT244 or OC 
antibodies (Fig. 4B and C). When evaluating regional differences in the distribution of 
immunolabeling of different deposits, we observed no striking differences (data not shown).  
In control cases, using antibodies NT244 and OC we observed diffuse parenchymal 
deposits, occasional cored plaques, and vessel wall deposits in five, while in another five we 
did not observe any immunoreactivities. Intraneuronal immunoreactivity was not seen. All 
other deposits were immunolabeled as seen in AD cases: only a portion of diffuse 
granulofibrillar Aβ deposits were immunopositive with antibody 9D5 (see Supplemental 
Fig. 3). 
 
Discussion 
Like other amyloidogenic proteins, the Aβ protein can adopt a number of different 
molecular assembly states, from soluble monomers and oligomers to insoluble fibrillar 
structures [24]. There is increasing evidence that Aβ oligomers represent the primary 
neurotoxic species and are closely associated with key elements of AD pathogenesis, such as 
synaptic dysfunction and neuron loss. Since the first description of oligomers, several 
alternative forms have emerged as possible disease-causing agents [29]. However, Aβ 
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oligomers comprise a heterogenous group (e.g. dimers, Aβ*56 and globulomers) displaying 
different toxic activities and are formed under various conditions [30-32].  
In our view, the current challenge of antibody-based AD therapy is the elimination or 
neutralisation of pathological intermediate oligomers, without depleting their monomeric or 
higher-ordered fibrillar forms. Antibodies targeting linear Aβ epitopes are less favorable due 
to their inability to distinguish between physiological (monomeric) and pathological 
(oligomeric) derivates. Several conformation-dependent antibodies have been developed 
using different strategies. In addition, many oligomeric Aβ structures (and corresponding 
antibodies) have been reported so far, however, there is a lack of information whether these 
oligomers really exist in AD brain. O’Nuallain and Wetzel described conformation-
dependent antibodies (W01 and W02) that preferentially bind insoluble, mature fibrils, rather 
than soluble oligomers and monomers [33]. Another group generated a panel of 
conformational polyclonal antibodies (including A11 and OC) that selectively recognize Aβ 
oligomers and fibrils without detecting monomeric variants [23, 24]. These antibodies react 
with fibrillogenic proteins from other proteinopathies. This intriguing cross-reactivity 
suggests the existence of common three-dimensonal structures that are independent from the 
linear amino acid side chain information. In contrast, conformation-specific antibodies 
directed against ADDLs (Aβ1-42 oligomers) present no cross-reactivity with other 
amyloidogenic proteins and selectively bind Aβ oligomers and fibrils with little monomer 
binding [34, 35].  
We followed a different approach based on the concept that N-terminally truncated 
Aβ species, in particular AβpE3-x, represent an important element in the initiation of 
pathological cascades in AD [21]. It was recently shown that the presence of AβpE3-x induces 
neurotoxicity in vitro and in vivo [20, 36]. Furthermore, it was demonstrated that monomers 
of these N-terminally truncated variants are more prone to aggregate and rapidly form 
intermediate oligomeric assemblies (accelerated up to 250-fold compared to unmodified Aβ), 
implicating AβpE3-x as a putative seeding component [37]. In a first effort, we analysed the 
distribution of AβpE3-x in mouse models, sporadic and familial AD cases. Therefore, we 
generated two monoclonal antibodies directed against the linear Aβ epitope starting with 
pyroglutamate (mAb 2-48 and mAb 1-57). Comparison of their immunoreactivities with a 
generic pan-Aβ antibody (4G8) demonstrated high abundance and equal amounts of plaques 
staining with 4G8 and 2-48 [38]. Given the increasing interest in AβpE3-x, we integrated our 
previous research on N-terminally modified Aβ species into the oligomer concept and 
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developed the conformation-dependent monoclonal antibody 9D5 that selectively recognizes 
oligomeric assemblies of AβpE3-38 derivatives [39] . Size-exclusion chromatography followed 
by dot blot analysis revealed that 9D5 presents no cross-reactivity with Aβ1-42 variants 
(monomers to fibrils) and selectively detects a neoepitope generated by low-molecular 
weight AβpE3-x oligomers (4-10mer), but not monomers and dimers [22].  
In the current study, we further investigated the 9D5-specific staining properties of 
amyloid deposits in sporadic AD and age-matched control subjects. In line with other studies, 
formic acid remarkably enhanced Aβ immunostaining compared to other antigen retrieval 
methods, suggesting that the conformation recognized by 9D5 is also observed in fibril-
dominated Aβ deposits [40, 41]. 9D5 immunolabeled only a fraction of the total Aβ 
immunoreactivity that was visualized by the generic antibody NT244 (recognizing a linear 
epitope) and the conformation-dependent antibody OC (binding to a conformational epitope). 
Morphological classification of 9D5 immunopositive structures revealed that apparently the 
whole spectrum of Aβ deposits can be detected. Oligomer-specific immunoreactivity was 
also associated within large cored and diffuse plaques. Nonetheless, 9D5-immunoreactivity 
only partially overlapped with Aβ40-specific labeling, implicating differences in the 
molecular protein composition of amyloid plaques. Small punctuate clusters within neurons 
and scattered labeling surrounding individual cells were also seen in AD brains. Such 
perineuronal immunoreactivity is similar to that seen with ADDL-generated oligomeric 
antibodies and has been attributed to oligomer attachment to synapses (synaptic-type 
deposits), occuring at an early stage in AD pathology or even preclinically [42, 43]. 
Since the initial description of conformational-specific antibodies, an interesting issue 
was that they cross-react with various other fibrillogenic, disease-associated proteins. 
Addressing this issue, the major finding of the current study is that we could exclude cross-
reactivity with the most prevalent neurodegeneration-related amyloidogenic proteins. 
Furthermore, our study demonstrated that 9D5 detects only a minority of AD-related plaques 
in sporadic cases. To highlight its implication, it must be noted, that in human patients, the 
first active immunization trials using AN1792 were halted in phase 2, because of severe side 
effects (such as meningoencephalitis) and lack of clinical efficacy. Therefore passive 
immunization has become a valuable alternative [44, 45]. In this context, 9D5 represents a 
promising therapeutic strategy in the management of AD (see review [39]).  
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Table 1. Demographic data and examined anatomical regions of the cases involved in our 
study. Abbreviations: AD: Alzheimer disease, B&B: Braak and Braak stage, DLB: dementia 
with Lewy bodies, PD: Parkinson`s disease, MSA: multiple system atrophy, PSP: progressive 
supranuclear palsy, CBD: corticobasal degeneration, PiD: Pick`s disease, FTLD-TDP: 
frontotemporal lobar degeneration, ALS: amyotrophic lateralsclerosis, CJD: Creutzfeldt-
Jakob disease, M: methionine, V: valine, Ent Cx: entorhinal cortex, Temp Cx: temporal 
cortex, SN: substantia nigra, Cbll: cerebellum. 
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No. Case/Disease Age Sex Examined regions 
1 AD related changes (B&B III) 78 F Hippocampus+Ent Cx+Temp Cx 
2 AD related changes (B&B III) 84 M Hippocampus+Ent Cx+Temp Cx 
3 AD related changes (B&B V) 76 F Hippocampus+Ent Cx+Temp Cx 
4 AD related changes (B&B V) 81 M Hippocampus+Ent Cx+Temp Cx 
5 AD related changes (B&B V) 76 F Hippocampus+Ent Cx+Temp Cx 
6 AD related changes (B&B VI) 75 F Hippocampus+Ent Cx+Temp Cx 
7 AD related changes (B&B VI) 88 F Hippocampus+Ent Cx+Temp Cx 
8 AD related changes (B&B VI)+TDP 85 F Hippocampus+Ent Cx+Temp Cx 
9 AD related changes (B&B VI)+TDP 86 F Hippocampus+Ent Cx+Temp Cx 
10 Control-1 78 F Hippocampus+Ent Cx+Temp Cx 
11 Control-2 82 F Hippocampus+Ent Cx+Temp Cx 
12 Control-3 88 F Hippocampus+Ent Cx+Temp Cx 
13 Control-4 90 F Hippocampus+Ent Cx+Temp Cx 
14 Control-5 70 M Hippocampus+Ent Cx+Temp Cx 
15 Control-6 70 M Hippocampus+Ent Cx+Temp Cx 
16 Control-7 73 M Hippocampus+Ent Cx+Temp Cx 
17 DLB-1 78 M Temporal Cx 
18 DLB-2 82 M Temporal Cx 
19 DLB-3 81 F Temporal Cx 
20 PD-1 81 M Mesencephalon (SN) 
21 PD-2 62 M Mesencephalon (SN) 
22 PD-3 81 M Mesencephalon (SN) 
23 MSA-1 75 F Pons 
24 MSA-2 52 M Pons 
25 MSA-3 54 M Pons 
26 PSP-1 69 M Basal Ganglia 
27 PSP-2 63 M Basal Ganglia 
28 PSP-3 68 F Basal Ganglia 
29 CBD-1 70 M Basal Ganglia 
30 CBD-2 69 M Basal Ganglia 
31 CBD-3 67 M Basal Ganglia 
32 AGD-1 83 M Hippocampus+Ent Cx+Temp Cx 
33 AGD-2 85 F Hippocampus+Ent Cx+Temp Cx 
34 AGD-3 81 M Hippocampus+Ent Cx+Temp Cx 
35 PiD-1 63 F Hippocampus+Ent Cx+Temp Cx 
36 PiD-2 59 F Hippocampus+Ent Cx+Temp Cx 
37 PiD-3 70 F Hippocampus+Ent Cx+Temp Cx 
38 FTLD-TDP-1 66 M Hippocampus+Ent Cx+Temp Cx 
39 FTLD-TDP-2 55 F Hippocampus+Ent Cx+Temp Cx 
40 FTLD-TDP-3 62 F Hippocampus+Ent Cx+Temp Cx 
41 ALS-1 56 F Spinal cord (cervical) 
42 ALS-2 63 M Spinal cord (cervical) 
43 ALS-3 62 F Spinal cord (cervical) 
44 CJD MM-1 71 F Hippocampus+Ent Cx+Temp Cx+Cbll 
45 CJD MV-2 72 F Hippocampus+Ent Cx+Temp Cx+Cbll 
46 CJD VV-2 59 F Hippocampus+Ent Cx+Temp Cx+Cbll 
47 Binswanger disease 49 F Basal Ganglia 
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Figure legends 
 
Fig. 1. Immunostaining for 9D5: comparison of different antigen retrieval methods. 
Compared to no pretreatment, 60-min steam heat pretreatment in citric acid buffer pH 6 failed 
to improve staining of β-amyloid deposits. However, 3-min formic acid (FA) pretreatment 
significantly increased staining intensity of extracellular Aβ plaques. Combined treatment of 
heat and FA further enhanced 9D5 immunoreactivity. Scale bars: A, 500 µm; B, 200 µm; C, 
100 µm. 
 
Fig. 2. Representative images of various pathological structures in neurodegenerative 
diseases. These lack immunopositivity for the 9D5 antibody (second and fourth column from 
left). Phospho-Tau immunoreactive dystrophic neurites (asterisk), granulovacuolar 
degeneration (arrow), neurofibrillary tangles (arrowhead) in AD (A) and PSP with tufted 
astrocytes and globular tangles (B); Pick bodies in Pick`s disease (C). α-Synuclein 
immunopositive brainstem (D; arrowhead indicates neuromelanin particles) and cortical (E; 
note the presence of Aβ deposits) Lewy bodies and Lewy neurites in PD and DLB, 
respectively; glial cytoplasmic inclusions in MSA (F). Phospho-TDP-43 immunoreactive 
neuronal cytoplasmic and neuritic deposits in an Alzheimer`s disease case with limbic TDP 
pathology (G; note the presence of Aβ deposits). Pathological vessels in Binswanger 
encephalopathy (H). PrP immunopositive synaptic (I) and plaque (J) deposits in sporadic 
Creutzfeldt-Jakob disease. Scale bar in A represents 30 µm for A-E, G and H, 50 µm for F 
and J, and 80 µm for I. 
 
Fig. 3. Comparison of immunoreactivities using different antibodies.  
Occasional intracytoplasmic dots are seen in small neurons of the entorhinal cortex using the 
9D5 antibody (A), whereas much more perineuronal accumulation is detected by antibody 
NT244 (B). Similarly, granulofibrillar diffuse deposits (C, D) and the rim of cored plaques 
(E, F) are more extensively immunolabeled by NT-244 (D, F) than by 9D5 (C, E). Note the 
lack of intracytoplasmic staining in the neurons with prominent lipofuscin accumulation (C, 
indicated by arrowheads). Furthermore, combined immunolabeling of 9D5 and anti-Aβ1-40 
produces not fully overlapping staining patterns (G). Scale bar in A represents 15 µm for A-D 
and G, and 10 µm for E, F. 
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Fig. 4. Immunostaining for 9D5 reveals cerebral amyloid angiopathy (CAA), subpial band-
like, perivascular, fleecy, and focal deposits (A). Quantification of morphometric data of 
immunolabeled deposits in the CA1 subregion of the hippocampus, in the entorhinal (EC) 
and temporal cortex (GTS: Gyrus temporalis superior) using antibodies 9D5, NT244, and OC 
(B). ***p < 0.001; **p < 0.01; *p < 0.05. Note the difference in the extent of immunostained 
deposits as represented by adjacent sections of the temporal cortex (C). Scale bar in A 
represents 20 µm for the left image, 10 µm for the three images on the right, and 30 µm for 
C. Asterisks in C indicate the same vessel. 
 




